In this #NASHDAY 2022 Preview conversation, Stephen Harrison discusses new approaches to Phase 3 clinical trial design and endpoint evaluation, changes he describes as “real, granular progress in drug development.”
The SurfingNASH team (Jörn Schattenberg, Louise Campbell, Roger Green) join Global Liver Institute NASH Programs Director Jeff McIntyre for the wrap-up panel of #NASHDay 2022.
The Big Band (Stephen Harrison, Jörn Schattenberg, Louise Campbell, Roger Green) convenes on the eve of #NASHDay 2022 to ask what has changed in the Fatty Liver world in the last twelve months and to recognize the powerful impact of patient advocacy.
Louise Campbell and Rachel Zayas interview Altimmune Chief Medical Officer Scott Harris, and Rachel interviews Antaros Medical Vice President of Global Business Development Caleb Roberts in this mash up of two shorter interviews from our coverage of the 5th Global NASH Congress.
Louise Campbell interviews Julius Clinical Chief Scientific Officer Diederick Grobbee about Julius’s GRIP Program and the general value of NAFLD Screening in Primary Care practices.
Rachel Zayas interviews Madrigal Pharmaceuticals Founder, Chief Medical Officer and President of R & D Rebecca Taub on the design and some findings from the MAESTRO clinical trials and the importance of patient advocacy.
As the 5th Global NASH Congress comes to an end, Louise Campbell and Rachel Zayas compare notes on the key presentations at the Congress and core NAFLD topics and ideas they are taking away from the event.
Louise Campbell shares highlights from the recent 5th Global NASH Congress, while Jörn Schattenberg and Roger Green share questions and related comments. This conversation focuses on the emerging market for devices that provide portable liver scans and the quality-of-life implications of liver volume changes.
Louise Campbell shares highlights from the recent 5th Global NASH Congress, while Jörn Schattenberg and Roger Green share questions and related comments.
NASH Tsunami covers the 5th Global NASH Congress, with Louise Campbell and Rachel Zayas conducting speaker interviews and Jouise, Rachel, Jörn Schattenberg and Roger Green commenting on conference themes and related areas of interest.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider how to move discussion of NASH Best Practices around NITs forward.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to explore benefits and best ways to “stack” NASH biomarkers to create a more robust efficacy measure for clinical trials.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider goals and applications for NASH Biomarkers.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss Five Key Takeaways in two recent presentations on NITs. He challenges the group to reconsider what NIT (and testing) NASH Best Practices should become.
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
The discussion of drugs in development continues, with specific focus on the treasure trove of data Intercept is producing for OCA and why combination therapy will probably be critical element in the long-term treatment strategy for NASH.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
Roger Green interviews physician, author, and entrepreneur Marcus Ranney about his experiences, the ability of data and digital health to empower health seekers, and the foundational vision that led him to form Human Edge and develop the Mito app.
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway. This conversation centers around areas for controversy, including data-driven patient empowerment and what the proper name for this disease should be.
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway.
Co-chair Jeff Lazarus joins the Surfers (including co-chair Jörn Schattenberg) to review last week’s Innovations in NAFLD Care 2022 conference PLUS Roger Green interviews one of the events’ speakers, Human Edge CEO Dr. Marcus Ranney
Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss the role of NAFLD patient advocacy in the Fatty Liver community. This conversation centers around the importance of taking action locally and enhancing communication across stakeholder groups if we are to keep increasing momentum over time.
Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss value of NAFLD patient advocacy in the Fatty Liver community. This conversation focuses on whether there is an actual integrated community along with key areas to build successes.
Achim Kautz and Andrew Scott discuss some of their successes in patient advocacy, while Louise Campbell raises a question about which patients should be the focus of advocates’ activities.
Achim Kautz, Andrew Scott and Jörn Schattenberg share their experiences in talking with public officials about Fatty Liver disease and liver health.
Leading NAFLD patient advocates Achim Kautz and Andrew Scott discuss how their personal backgrounds (that are quite different) brought them to the place where they work in serving the Fatty Liver community.
Patient advocates Andrew Scott from the Global Liver Institute and Achim Kautz from Germany share their backgrounds, perspective, goals, and strategies with the Surfers.
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on a range of topics.
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on presentations regarding
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on presentations that discuss innovative ways to explore drugs in development through precision cut ex vivo hepatic tissue modeling, omics and liquid biopsy.
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on presentations regarding gut microbiome and other nutritional issues.
Ian Rowe and Rachel Zayas join the Surfers to help Surfing the NASH Tsunami preview the 5th Global NASH Congress.
This conversation between Donna Cryer, Louise Campbell and Roger Green focuses largely on NASH patient care and digital health issues. Listen to learn why Roger Green believes the liver (and particularly Fatty Liver) might benefit more from digital therapeutics than any other organ system.
Donna Cryer joins Louise Campbell and Roger Green to share three pieces of news: an NCQA paper on NASH; an American Heart Association paper on the link between NASH and heart disease, and the Global Liver Institute’s new “Liver Health is Public Health” campaign.
Naim Alkhouri joins Louise Campbell and Roger Green to discuss some of his recent investigator-initiated research projects that focus on future NASH therapies. These include a project evaluating the impact of the behavioral diet app Noom on liver health and a series of others evaluating digital therapeutics and their ability to improve patients’ liver health.
Naim Alkhouri joins Louise Campbell and Roger Green to discuss two of his recent publications, one estimating US prevalence based in NHANES data and the other looking at how the treatment choices a physician makes for Type 2 Diabetes can affect long-term NAFLD and NASH incidence.
Jörn Schattenberg and Louise Campbell share their view about the “best” paths for NAFLD Care Delivery in major countries today.
Louise Campbell and Roger Green interview Arizona Liver Health Institute V.P. of Academic Affairs and Fatty Liver Program Director Naim Alkhouri and Global Liver Institute Founder and CEO Donna Cryer about their recent projects and accomplishments.
As Jörn Schattenberg joins the permanent Surfing crew, he sits with Louise Campbell and Roger Green to share his background and focus and to discuss where SurfingNASH.com will take NASH Tsunami in its third full year.
Naim Alkhouri and Mazen Noureddin discuss the kinds of tools they developed in pursuit of a task Stephen Harrison defines as “making the wheel run smoother.”
The NAIL-NIT leaders explore exactly what makes it so challenging to develop FDA test criteria that match the overall picture of whether a drug is succeeding or not.
NAIL-NIT Retrospective Analysis co-chairs Naim Alkhouri and Jörn Schattenberg share their general plans and “passionate first projects” for this group.
NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin describe the conversation that stimulated them to develop NAIL-NIT and why they are so committed to moving NAFLD diagnostics Beyond the Biopsy.
News about a new company to steer Surfing the NASH Tsunami into the future plus new roles for Stephen Harrison and Jörn Schattenberg
NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin and retrospective analysis co-leads Naim Alkhouri and Jörn Schattenberg join Louise and Roger to discuss designs and plans for NAIL-NIT retrospective analysis.
Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
Did you ever wonder why leaders believe the care continuum necessary to bring the NASH pandemic under control will require so many types of healthcare providers and such a broad effort?
Learn about the rationale and focus for Sessions 1 and 2 of the Innovations in NAFLD Care Workshop and NASH epidemiology for action.
Learn about the history and interests that led Professors Jeff Lazarus and Jörn Schattenberg to launch the Innovations in NAFLD Care 2022 Workshop
Conference founders and directors Jeffrey Lazarus and Jörn Schattenberg join Roger Green to preview the inaugural Innovations in NAFLD Care 2022 conference, scheduled for May 6 and 7 In Barcelona and on-line.
Which riddles around hepatic regeneration can we foresee answering in the future as the capabilities around single-cell genomics and its successors continue to expand rapidly?
This episode focuses on the history of single-cell genomics up through spatial transcriptomics and beyond and raises questions about the new things we can learn and the demand these improved techniques place on other elements in the research process.
What are the implications of the targeted NASH therapies of the future on NASH drug development today?
Scott Friedman discusses that background for the potential breakthrough work from Jon Epstein at the University of Pennsylvania on how combined mRNA/CAR-T therapy can regress fibrosis in mouse CVD models.
What do recent findings in mRNA/CAR-T anti-fibrotic therapies and advanced NASH omics promise for the future of treating NAFLD and NASH?
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
This episode is Sponsored by Resoundant.
What can a NASH Disease Model tell us about the value of FIB-4 in the NASH Diagnostic Pathway vs. more expensive tests with stronger predictive values, both today and as other NITs improve?
This episode is Sponsored by Resoundant.
Panelists explore several key questions that have arisen at recent meetings like Liver Connect, including the value of waist circumference measurements, the interplay of NAFLD and alcohol consumption and the definition of a “fast progressor.”
